Co-Diovan 320 mg/25 mg filmom obložene tablete
Name | Co-Diovan 320 mg/25 mg filmom obložene tablete |
---|---|
Marketing Authorisation Number | HR-H-063837675 |
Active Substance | valsartan hidroklorotiazid |
Composition | svaka filmom obložena tableta sadrži 320 mg valsartana i 25 mg hidroklorotiazida |
Pharmaceutical Form | filmom obložena tableta |
Manufacturer | Novartis Pharma GmbH, Nürnberg, Njemačka Novartis Farma S.p.A., Torre Annunziata (Napulj), Italija Novartis Farmacéutica S.A., Barcelona, Španjolska |
Marketing Authorisation Holder | Novartis Hrvatska d.o.o., Radnička cesta 37b, Zagreb, Hrvatska |
Marketing Authorisation Date | 09.02.2016 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/15-02/314 |
Registration Number | 381-12-01/30-16-06 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | C09DA03 |
Medicinal product marketed in the Croatia | Nestašica |
SmPC | download |
PL | download |
Public Assessment Report | download |
Packaging
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |